evipedia.ai
← Back

Arjuna for Health & Longevity

Evidence Review created on 10/23/2026 using AI4L / Opus 5.5

Also known as: Terminalia arjuna, Arjun, Arjun Tree, Arjuna Bark, Kakubha, Koha, Kahu, White Marudah

Motivation

Arjuna (Terminalia arjuna) is a large tree native to India whose bark has served as a heart remedy in traditional Indian medicine for centuries. Today the powdered bark and its water or alcohol extracts are sold worldwide as dietary supplements for heart and blood-vessel health. The bark contains plant compounds thought to strengthen the heart’s pumping action and protect blood vessels from damage.

Interest outside India grew from a series of small hospital studies in India on chest pain caused by narrowed heart arteries, heart failure and blood fats, and more recently from company-funded studies of a branded extract in healthy adults. Because heart and blood-vessel disease remains a leading cause of death and disability with age, a low-cost plant product with a long traditional record draws attention from people seeking to protect their heart over decades.

This review examines the human evidence on arjuna’s benefits and risks, the quality and independence of that evidence, its interactions with common medicines, and the doses and products studied, to clarify where arjuna stands for health- and longevity-focused adults.

Benefits - Risks - Protocol - Conclusion

Expert commentary and narrative reviews that discuss arjuna’s cardiovascular use and its evidence in depth.

Only four items are listed because no further in-depth expert overview of arjuna was found. Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io have published no content on arjuna as of October 2026, according to web and on-site searches.

Grokipedia

  • Terminalia arjuna

    AI-generated encyclopedic entry covering the tree’s botany, Ayurvedic bark preparations, main plant compounds, summarized cardiovascular trial findings and reported side effects.

Examine

  • Terminalia arjuna

    Independent evidence summary noting that arjuna improved heart failure in some studies and affected blood pressure inconsistently, with dosage and safety information on bark extracts.

ConsumerLab

No ConsumerLab article on arjuna exists. The site’s search returns only an answer page on Carditone, a multi-herb blood-pressure product that contains arjuna, and an ashwagandha product review; ConsumerLab has not tested arjuna products.

Systematic Reviews

Systematic reviews and meta-analyses of arjuna in chronic stable angina, heart failure and high blood fats.

No systematic review or meta-analysis dedicated to arjuna’s adverse effects was found; its principal risks are represented only by individual trials and laboratory studies.

Mechanism of Action

Arjuna bark contains triterpenoids (arjunic and arjunolic acid), triterpene glycosides (arjunetin, arjunosides), flavonoids, tannins, oligomeric proanthocyanidins and minerals such as calcium (Kapoor et al., 2014). Proposed actions come mostly from animal and cell studies:

  • Heart muscle support: glycosides are proposed to increase the force of heart contraction (positive inotropy) and to protect heart tissue during reduced blood flow (ischemia) (Dwivedi, 2007).
  • Antioxidant and lipid effects: flavonoids and tannins scavenge free radicals, limit oxidative damage to blood fats, and lowered cholesterol in animals (Kapoor et al., 2014).
  • Anti-inflammatory signalling: the extract suppressed NF-κB (nuclear factor kappa B, a master switch for inflammatory genes) and restored PPAR-γ (peroxisome proliferator-activated receptor gamma, a regulator of cholesterol export and inflammation) in ApoE-deficient mice (mice bred to develop atherosclerosis, fatty plaque build-up in arteries) (Bhat et al., 2018).
  • Platelet inhibition: an ethanolic extract reduced aggregation of human platelets in the test tube (Malik et al., 2009).

A competing explanation from a rat study holds that part of the cardioprotection reflects suppressed thyroid hormone output, which would be undesirable in people with normal thyroid function (Parmar et al., 2006).

Pharmacology: no human data exist on half-life, tissue distribution or metabolism of arjuna’s constituents, and no receptor selectivity has been defined. Whole extracts, but not isolated triterpenoids, inhibited CYP3A4, CYP2D6, CYP2C9 and CYP1A (liver enzymes that break down many drugs) in human liver microsomes (liver-cell enzyme preparations) (Varghese et al., 2015; Varghese et al., 2014).

Historical Context & Evolution

Arjuna bark has been used in Ayurveda, India’s traditional medical system, for chest pain (“hritshool”) and other heart complaints for centuries, usually as a powder or a decoction boiled in milk (Dwivedi, 2007). Its original use was therefore cardiac, unlike many supplements repurposed later. A 1951 report described increased cardiac output in failing hearts but no change in healthy volunteers (cited in Sandhu et al., 2010).

From the 1990s, Indian clinicians ran small studies. Dwivedi’s Delhi group reported about half as many angina episodes after three months of bark powder in an uncontrolled study (Dwivedi & Agarwal, 1994). Bharani’s Indore group reported better heart failure measures and longer treadmill times in placebo-controlled crossover trials, in which each patient receives both treatments in turn (Bharani et al., 1995; Bharani et al., 2002). These findings made arjuna a candidate for health optimization as an inexpensive add-on for heart protection.

Opinion then became more cautious. A 2014 meta-analysis rated every angina study at high risk of bias (Kaur et al., 2014), and the largest placebo-controlled heart failure trial found no change in ejection fraction at 12 weeks (Maulik et al., 2016; one co-author was affiliated with Dabur India, an Ayurvedic manufacturer). Since 2017, trials of a branded extract in healthy adults (Girandola & Srivastava, 2017; co-authored by an employee of Enovate Biolife, which markets the extract) have repositioned arjuna as a cardiac-fitness supplement. Trials on both sides remain small, so arjuna’s standing is still open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the clinical-endpoint trials are small single-centre studies, and each outcome is either reported by only one research group or contradicted by a larger trial or a meta-analysis.

Medium 🟩 🟩

Cardiac Pumping Function and Exertional Fatigue in Healthy Adults ⚠️ Conflicted

Two placebo-controlled trials of a standardized extract (Oxyjun) reported higher left ventricular ejection fraction (LVEF) and lower Borg-scale perceived exertion (a 6–20 effort rating) in 32 exercising men (Girandola & Srivastava, 2017) and higher LVEF in 72 overweight adults (Srivastava et al., 2022). Both come from one group tied to the maker, Enovate Biolife. The 2022 abstract claims less fatigue; full results show no significant difference from placebo. Normal-range LVEF gains are not linked to fewer heart events. Net: the LVEF rise is consistent, the fatigue benefit unconfirmed.

Magnitude: LVEF rose 3.64 percentage points (95% CI, confidence interval: the range likely to contain the true value, 2.47–4.81) on extract versus 0.14 points (95% CI −0.32 to 0.60) on placebo over 56 days; between-group p<0.0001 (p: probability that the difference arose by chance) (Srivastava et al., 2022).

Low 🟩

Angina Symptoms and Exercise Tolerance ⚠️ Conflicted

In a placebo-controlled crossover trial of 58 men with stable angina (chest pain from narrowed heart arteries), bark extract 500 mg every 8 hours reduced angina and lengthened treadmill time (Bharani et al., 2002). A meta-analysis found no pooled treadmill difference (Kaur et al., 2014). Net: suggestive but unconfirmed.

Magnitude: Treadmill exercise lasted 6.14 minutes on arjuna versus 4.76 minutes on placebo (crossover, p<0.005) (Bharani et al., 2002); the meta-analysis found no significant pooled difference in exercise duration versus control.

Heart Failure Symptoms and Heart-Muscle Remodeling ⚠️ Conflicted

In 12 patients with severe heart failure, extract improved symptoms versus placebo (Bharani et al., 1995); a 2026 meta-analysis found reduced heart-muscle mass (Kumar et al., 2026). A 100-patient trial found no symptom or walking-distance benefit (Maulik et al., 2016). Net: symptom benefit remains unconfirmed.

Magnitude: Left ventricular mass pooled mean difference −44.32 versus control across nine trials (p=0.0001) (Kumar et al., 2026); the 100-patient trial found no significant between-group difference in symptom class or 6-minute walk distance at 12 weeks (Maulik et al., 2016).

Blood Lipids ⚠️ Conflicted

In 105 coronary patients, bark powder 500 mg/day lowered total and LDL cholesterol over 30 days (Gupta et al., 2001); a 116-patient trial lowered triglycerides (Kapoor et al., 2015). Healthy adults showed no LDL change (Srivastava et al., 2022). Net: modest, inconsistent effects.

Magnitude: Total cholesterol −9.7% and LDL −15.8% within the arjuna group, with no significant change in the placebo group; not compared between groups (Gupta et al., 2001). Pooled HDL +3.53 mg/dL in heart failure trials (p=0.0006) (Kumar et al., 2026).

Blood Pressure ⚠️ Conflicted

Added to telmisartan (a blood-pressure drug), arjuna 3 g/day lowered blood pressure more than placebo in 44 hypertensive patients (Nazir et al., 2026). In healthy young adults, systolic pressure fell versus placebo (Sandhu et al., 2010), but not in overweight adults with high-normal pressure (Srivastava et al., 2022). Net: uncertain.

Magnitude: Systolic pressure fell 4.2% more than with placebo over 8 weeks (123.0 to 117.8 mmHg on arjuna, n=10; between-group p=0.003) (Sandhu et al., 2010). In overweight adults with high-normal pressure, systolic change was −0.83 versus +0.26 mmHg, not significantly different (Srivastava et al., 2022).

Blood Glucose in Type 2 Diabetes

In 60 patients on metformin, adding bark 1 g twice daily lowered HbA1c (glycated hemoglobin, a three-month glucose average) as much as adding sitagliptin (a diabetes drug) over 12 weeks (Prakash et al., 2024). Indirect: tested only alongside metformin, without placebo.

Magnitude: HbA1c fell 0.89 points with arjuna plus metformin versus 0.90 points with sitagliptin plus metformin; difference not significant (p>0.05) (Prakash et al., 2024).

Speculative 🟨

Endothelial Function

Extract improved flow-mediated dilation (artery widening after cuff release) versus placebo in 18 male smokers over 2 weeks (Bharani et al., 2004). This marker is not validated as a treatment target.

Anti-Inflammatory and Antioxidant Effects

Arjuna lowered inflammatory markers in 116 coronary patients (Kapoor et al., 2015) and lipid peroxides (markers of oxidative fat damage) (Gupta et al., 2001). These unvalidated biomarkers have no proven clinical meaning.

Antiplatelet and Anti-Atherosclerotic Activity

Extract reduced human platelet aggregation in the test tube (Malik et al., 2009) and atherosclerotic lesions in ApoE-deficient mice (Bhat et al., 2018). The basis is laboratory and animal data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants that modify arjuna’s benefits; variants in CYP2D6 or CYP3A4 would more plausibly alter exposure to co-prescribed drugs than arjuna’s own effect.
  • Baseline biomarkers: Lipids fell in coronary patients (Gupta et al., 2001) but not with near-normal lipids (Srivastava et al., 2022); in reduced-LVEF heart failure, LVEF rose in a 12-patient trial (Bharani et al., 1995) but not a 100-patient trial (Maulik et al., 2016).
  • Sex: Most trials enrolled mainly or only men (Bharani et al., 2002); the 2022 trial was 37.5% women without separate analysis, so sex differences in benefit are unknown.
  • Pre-existing conditions: Benefits were reported mainly in stable angina, heart failure, hypertension and diabetes; overweight adults with near-normal values showed no blood-pressure or lipid change (Srivastava et al., 2022), so people with established risk factors may have more room to respond.
  • Age: Most participants were middle-aged; coronary patients averaging about 61 years took arjuna for up to 4.75 years (Dwivedi et al., 2019), but benefit beyond age 75 is unstudied.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small trials that rarely report placebo-group rates, plus animal and test-tube studies.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial has shown any adverse event occurring more often with arjuna than with placebo or usual care.

Low 🟥

Gastrointestinal Discomfort, Constipation and Headache ⚠️ Conflicted

Pooled angina studies recorded constipation, headache, body ache and abdominal discomfort (Kaur et al., 2014); a long-term cohort noted gastritis (stomach-lining inflammation) (Dwivedi et al., 2019). Placebo-controlled trials found no excess (Srivastava et al., 2022). Net: mild, possibly unrelated.

Magnitude: 15 adverse events among 78 patients in two studies (constipation 4, headache 3); no comparison-group rates reported (Kaur et al., 2014). Adverse events in 3 of 40 on extract versus 1 of 41 on placebo, all judged unrelated (Srivastava et al., 2022).

Heavy-Metal Contamination

Ayurvedic products sold online often contained lead, mercury or arsenic, especially metal-mixed (rasa shastra) formulas (Saper et al., 2008). Indirect: arjuna products were not analyzed separately, so the risk for single-herb bark extracts is unquantified.

Magnitude: 20.7% (95% CI 15.2–27.1%) of 193 Ayurvedic products contained detectable toxic metals; no control group (Saper et al., 2008).

Additive Blood-Pressure and Glucose Lowering with Medications ⚠️ Conflicted

Arjuna lowered blood pressure further when added to telmisartan (Nazir et al., 2026) and lowered glucose alongside metformin (Prakash et al., 2024), implying a risk of low blood pressure or low blood sugar. Indirect: both trials monitored adverse events and recorded no such episodes. Net: a plausible but unobserved risk.

Magnitude: Not quantified in available studies. Neither trial reported any episode of low blood pressure or low blood sugar, so no event rate exists.

Transient Heart Failure ⚠️ Conflicted

Pooled angina studies recorded one case of transient cardiac failure, plus single cases of dizziness and ankle swelling (Kaur et al., 2014); causality was not assessed. A 100-patient placebo-controlled heart failure trial found the extract well tolerated (Maulik et al., 2016). Net: an isolated report without a confirmed link.

Magnitude: 1 case of transient cardiac failure among 78 patients in two studies; no comparison-group rate reported (Kaur et al., 2014).

Speculative 🟨

Liver Injury ⚠️ Conflicted

High-dose extract raised liver lipid peroxidation in rats (Parmar et al., 2006). A placebo-controlled trial found no liver-enzyme rise (Srivastava et al., 2022). Net: an animal-only signal, absent in humans at studied doses.

Drug-Metabolizing Enzyme Inhibition

Extracts inhibited CYP3A4, CYP2D6, CYP2C9 and CYP1A in human liver microsomes (Varghese et al., 2015; Varghese et al., 2014) and lowered metoprolol levels in rats (Varghese et al., 2016). No human interaction study exists.

Bleeding Tendency

Antiplatelet activity in test-tube studies of human platelets (Malik et al., 2009) suggests added bleeding with anticoagulant or antiplatelet drugs (medicines that slow blood clotting). The basis is mechanistic; trials reported no bleeding events.

Thyroid Hormone Suppression

Bark extract lowered thyroid hormone levels in rats (Parmar et al., 2006). Human thyroid effects are unstudied, so hypothyroidism (underactive thyroid) risk rests on animal data only.

Male Reproductive Toxicity

Bark extract damaged cultured rat Leydig cells (testosterone-producing testicular cells) (Banerjee et al., 2021). No human fertility data exist; the basis is laboratory only.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP2D6 poor metabolizers and carriers of reduced-function CYP2C9 variants already clear some drugs slowly; added enzyme inhibition by arjuna could raise those drug levels further (theoretical).
  • Baseline biomarkers: Low resting blood pressure, borderline TSH (thyroid-stimulating hormone) or raised liver enzymes increase the consequences of arjuna’s theoretical effects; one trial excluded TSH below 0.4 or above 4.0 mIU/L (NCT04715126).
  • Sex: No sex-specific adverse-event data exist; pregnancy and breastfeeding are unstudied, and trials excluded pregnant or lactating women (NCT04715126).
  • Pre-existing conditions: Anticoagulant use, thyroid disease, liver or kidney disease and low blood pressure raise theoretical risk; heart failure patients on several drugs face greater interaction potential.
  • Age: Older adults take more CYP-cleared medicines and are more prone to dizziness on standing; coronary patients averaging about 61 years reported only gastritis and constipation over up to 4.75 years (Dwivedi et al., 2019).

Key Interactions & Contraindications

  • Blood-pressure drugs (telmisartan, amlodipine, metoprolol): Monitor — additive lowering occurred when arjuna was added to telmisartan (Nazir et al., 2026); consequence: dizziness or low blood pressure. Mitigation: home blood-pressure checks during the first 2–4 weeks.
  • CYP2D6-cleared beta-blockers (heart-rate-slowing drugs: metoprolol, carvedilol, nebivolol): Caution (theoretical) — arjuna lowered metoprolol levels and effect in rats (Varghese et al., 2016); consequence: weaker heart-rate or blood-pressure control. Mitigation: heart-rate and blood-pressure monitoring.
  • Drugs cleared by CYP3A4 (statins, the cholesterol-lowering drugs atorvastatin and simvastatin; tacrolimus, cyclosporine): Caution (theoretical) — inhibition in human liver microsomes (Varghese et al., 2015); consequence: higher drug levels and toxicity, such as statin muscle injury. Mitigation: drug-level checks for tacrolimus or cyclosporine.
  • Drugs cleared by CYP2C9 (warfarin, phenytoin, glipizide): Caution (theoretical) — microsome inhibition (Varghese et al., 2015); consequence: stronger drug effect, including bleeding with warfarin. Mitigation: INR (international normalized ratio, a clotting test) within 1–2 weeks of starting.
  • Anticoagulants and antiplatelet drugs (drugs that slow blood clotting: warfarin, apixaban, clopidogrel): Caution (theoretical) — antiplatelet activity in the test tube (Malik et al., 2009; Drugs.com monograph); consequence: increased bleeding risk. Mitigation: bruising and bleeding surveillance.
  • Diabetes drugs (metformin, glipizide, insulin): Monitor (theoretical) — glucose lowering alongside metformin, without a metformin-alone arm (Prakash et al., 2024); consequence: hypoglycemia (low blood sugar) with insulin or sulfonylureas (drugs that force insulin release). Mitigation: glucose self-monitoring for 2–4 weeks.
  • Thyroid drugs (levothyroxine, methimazole): Monitor (theoretical) — thyroid suppression in rats (Parmar et al., 2006); consequence: altered thyroid control. Mitigation: TSH check 6–8 weeks after starting.
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen, aspirin): Caution (theoretical) — combined antiplatelet effects by mechanism; consequence: increased bleeding, including stomach bleeding. Mitigation: avoiding regular combined use.
  • Over-the-counter drugs cleared by CYP2D6 (dextromethorphan, diphenhydramine): Monitor (theoretical) — CYP2D6 inhibition in microsomes (Varghese et al., 2015); consequence: altered drug levels and drowsiness. Mitigation: lowest effective over-the-counter dose.
  • Blood-pressure-lowering or antiplatelet supplements (hawthorn, garlic, ginkgo, fish oil): Caution (theoretical) — additive effects by mechanism; no interaction study exists; consequence: low blood pressure or bleeding. Mitigation: introducing one product at a time.
  • Glucose-lowering supplements (berberine, cinnamon, chromium): Monitor (theoretical) — additive glucose lowering by mechanism; berberine also inhibits CYP enzymes; consequence: low blood sugar in people on diabetes drugs. Mitigation: glucose self-monitoring.
  • Ashwagandha: No interaction observed — taken together with arjuna for 8 weeks by healthy young adults without adverse effects (Sandhu et al., 2010); severity: none identified; consequence: none reported.
  • Iron supplements: Monitor (theoretical) — bark tannins may bind non-heme (plant-type) iron; consequence: reduced iron absorption. Mitigation: separating doses by at least 2 hours.
  • Elective surgery: Caution (theoretical) — antiplatelet activity by mechanism; consequence: increased surgical bleeding. Mitigation: pausing about 2 weeks before surgery.

Populations who should avoid Arjuna:

  • Pregnant or breastfeeding women — no safety data; excluded from trials (NCT04715126) and listed as “avoid use” in a drug monograph
  • People with abnormal thyroid function: TSH below 0.4 or above 4.0 mIU/L, the exclusion threshold in NCT04715126
  • People with liver or kidney disease — trials required normal liver enzymes (AST, aspartate aminotransferase; ALT, alanine aminotransferase) and creatinine (NCT04715126)
  • People taking anticoagulants — excluded from trials (NCT04715126)
  • People with unstable or acutely symptomatic heart disease, or ongoing arrhythmia (irregular heart rhythm) — excluded from trials (NCT04715126; NCT02207101)
  • Children — no data
  • People with low blood pressure — general category; no source gives a threshold

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Tested single-herb product: Choosing a bark extract with third-party heavy-metal testing (USP, United States Pharmacopeia; NSF, a certification body) mitigates the contamination risk documented in Ayurvedic products (Saper et al., 2008).
  • Blood-pressure tracking: Home readings twice weekly for the first month mitigate excessive lowering when arjuna is combined with blood-pressure drugs; dizziness or readings clearly below the usual level prompt dose review.
  • Glucose self-monitoring: For users on insulin or sulfonylureas, fasting glucose checks during the first 2–4 weeks mitigate the risk of hypoglycemia from additive glucose lowering.
  • Liver enzyme checks: ALT and AST at baseline and after 8–12 weeks address the rat liver-injury signal; a rise above the laboratory reference range prompts stopping and medical review.
  • Thyroid check: TSH at baseline and after 2–3 months mitigates the theoretical thyroid-suppression risk; a trial used 0.4–4.0 mIU/L as its eligibility range (NCT04715126).
  • Medication review: A pharmacist review of CYP3A4-, CYP2D6- and CYP2C9-cleared drugs before starting mitigates enzyme-inhibition interactions (Varghese et al., 2015); warfarin users add an INR check.
  • Pre-surgery pause: Stopping about 2 weeks before elective surgery mitigates the theoretical bleeding risk from antiplatelet activity.
  • Iron separation: Taking arjuna at least 2 hours apart from iron supplements mitigates theoretical tannin-related iron malabsorption.
  • Dosing with food: Taking doses after meals, as in trials (NCT02207101), may reduce gastritis and abdominal discomfort.

Therapeutic Protocol

Each dose below is cited to its source; timing, cycling and titration details without a citation reflect common practice.

  • Bark extract, three times daily: 500 mg every 8 hours in angina and heart failure trials by Bharani’s Indore group (Bharani et al., 2002) and long-term use by Dwivedi’s Delhi group (Dwivedi et al., 2019).
  • Bark extract, twice daily: 500 mg twice daily as add-on in stable coronary disease (Kapoor et al., 2015); 750 mg twice daily of a standardized water extract in heart failure (Maulik et al., 2016).
  • Branded aqueous extract (Oxyjun): 400 mg once daily for 8 weeks in healthy adults (Srivastava et al., 2022); developed by Enovate Biolife and popularized through Life Extension’s Cardio Peak.
  • Traditional bark powder: 5 g twice daily for 8 weeks (Saleem et al., 2021) or 1.5 g twice daily (Nazir et al., 2026); Ayurvedic practice traditionally boils bark powder in milk as a decoction.
  • Competing approaches: Ayurvedic practice uses gram doses of whole bark powder; supplement practice uses standardized extracts at 400–1,500 mg/day. No trial has compared the two, so neither is established as superior.
  • Time of day: Trials gave once-daily extract after breakfast or lunch (NCT02207101; NCT03854786); no study compared morning with evening dosing.
  • Half-life: No human pharmacokinetic data exist for arjuna’s triterpenoids or flavonoids, so the half-life is unknown; disease trials used schedules every 8 or 12 hours.
  • Single versus split dosing: Crude bark and extracts were split two or three times daily in disease trials; the standardized 400 mg extract was taken once daily (Srivastava et al., 2022). No head-to-head comparison exists.
  • Genetic polymorphisms: No pharmacogenetic study exists; interaction concerns are greatest for CYP2D6 poor metabolizers or CYP2C9 variant carriers taking drugs cleared by those enzymes (theoretical).
  • Sex differences: Doses have not been studied by sex; the key angina trial enrolled men only (Bharani et al., 2002).
  • Age: Coronary patients averaging about 61 years took 500 mg three times daily for up to 4.75 years without laboratory abnormalities (Dwivedi et al., 2019); no dosing data exist beyond age 75.
  • Baseline biomarkers: Lipid and blood-pressure responses were reported mostly with elevated baseline values; with near-normal values, the 400 mg extract changed neither (Srivastava et al., 2022).
  • Pre-existing conditions: Heart failure trials gave arjuna only as an add-on to standard medicines (Maulik et al., 2016); no trial tested it as a replacement for guideline therapy.

Discontinuation & Cycling

  • Duration: Arjuna is used both short term (8–12-week trials) and long term; coronary patients took it for up to 4.75 years (Dwivedi et al., 2019). No evidence defines lifelong use.
  • Withdrawal effects: None reported; crossover trials used 2-week washout periods without reported rebound symptoms (Bharani et al., 1995).
  • Tapering: No tapering protocol has been studied; stopping at once is common practice, with blood pressure rechecked where blood-pressure drugs were reduced during arjuna use.
  • Cycling: No evidence shows tolerance or a need for cycling; some Ayurvedic practitioners use courses of several months followed by breaks, an approach that is unstudied.

Sourcing and Quality

  • Plant part and species: Products use stem bark of Terminalia arjuna; other species such as Terminalia chebula and Terminalia bellirica are different herbs with separate evidence.
  • Extract type: Water and alcohol extracts differ in composition; most trials used water extracts or crude bark, and CYP inhibition strength differed between extract types (Varghese et al., 2014).
  • Standardization: Most trial products lacked phytochemical standardization (Maulik & Talwar, 2012); the Oxyjun extract is standardized to 30% polyphenols and 15% glycosides (Life Extension Magazine).
  • Third-party testing: Heavy-metal testing matters given contamination in Ayurvedic products (Saper et al., 2008); USP or NSF certification, or a certificate of analysis for lead, mercury, arsenic and cadmium, indicates quality control.
  • Brands: Widely sold products include Himalaya Arjuna tablets, Life Extension Cardio Peak (Oxyjun), Banyan Botanicals bark powder and Ayush Herbs Arjuna-Heart (a multi-ingredient formula); ConsumerLab has not tested any of them for arjuna content.

Practical Considerations

  • Time to effect: Trial changes appeared at 1–2 weeks for angina, endothelial function (Bharani et al., 2002; Bharani et al., 2004), 30 days for cholesterol (Gupta et al., 2001), 8–12 weeks for ejection fraction and glucose (Srivastava et al., 2022; Prakash et al., 2024).
  • Common pitfalls: Replacing prescribed heart medicines with arjuna; buying untested multi-herb Ayurvedic formulas; confusing Terminalia species; and taking doses far below those used in trials.
  • Regulatory status: In the US, arjuna is sold as a dietary supplement, which the FDA (Food and Drug Administration) does not approve for safety or effectiveness before marketing (FDA questions and answers on dietary supplements).
  • Cost and accessibility: Arjuna is inexpensive and widely available online and in Indian pharmacies; cost and access are not barriers.
  • Payer and funding incentives: Arjuna and generic heart drugs are both inexpensive, so payers have no clear incentive to favor either; arjuna’s lack of patent protection limits funding for large trials, leaving the evidence to small academic and company studies.
  • Conflicts of interest: The healthy-adult trials were run by staff of the extract’s maker, Enovate Biolife (Srivastava et al., 2022); the null heart failure trial included a Dabur India co-author (Maulik et al., 2016).

Interaction with Foundational Habits

  • Sleep: Direction: none documented. No study measured sleep outcomes, and no stimulant constituents have been identified in the bark; dosing time can therefore follow meal timing rather than sleep timing.
  • Nutrition: Direction: indirect. Bark tannins may reduce non-heme iron absorption (theoretical), and separating doses from iron supplements is common practice; the cholesterol-lowering trial gave all groups a heart-healthy diet, so diet may be part of the effect (Gupta et al., 2001).
  • Exercise: Direction: potentiating (tentative). Company-sponsored trials reported higher ejection fraction and lower perceived exertion in exercising adults (Girandola & Srivastava, 2017); VO2 max (maximal oxygen uptake) rose within the arjuna group but not versus placebo (Sandhu et al., 2010). No blunting of training adaptation was reported.
  • Stress management: Direction: none documented in humans. A mouse study reported reduced anxiety-like behavior through serotonin and GABA (gamma-aminobutyric acid, the main calming brain messenger) pathways (Chandra Sekhar et al., 2017); no human cortisol or stress-scale data exist.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference points for arjuna’s expected effects and theoretical risks: seated blood pressure, a lipid panel, liver enzymes, TSH and, in people with diabetes, HbA1c. People with heart disease often already have a recent echocardiogram (heart ultrasound) giving LVEF; repeat scans follow clinical need rather than supplement tracking. Warfarin users add a baseline INR.

Ongoing monitoring follows this cadence: home blood pressure weekly for the first month, then monthly; lipids, liver enzymes and TSH at 8–12 weeks, then every 6–12 months during continued use; HbA1c every 3 months in diabetes; and INR within 1–2 weeks of starting for warfarin users. Success is defined as a change, against personal baseline, in the markers arjuna was started to influence, with no rise in liver enzymes or shift in TSH.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <130/80 mmHg (2017 ACC/AHA guideline target) Expected to change; safety check for excess lowering ACC/AHA: American College of Cardiology/American Heart Association; source Whelton et al., 2018; their clinician members earn revenue from treating high blood pressure, and the lower target widens the treated population. Conventional reference: normal <120/80 mmHg. Seated after 5 minutes’ rest, same time of day
LDL cholesterol No established target; track change from own baseline Expected to change Pair with HDL and triglycerides; non-fasting acceptable
HDL cholesterol No established target; track change from own baseline Expected to change Raised in pooled heart failure trials (Kumar et al., 2026); pair with LDL and triglycerides
Triglycerides No established target; track change from own baseline Expected to change Fasting 9–12 hours improves accuracy
ALT and AST ALT 7–56 U/L; AST 10–40 U/L (standard reference range) Safety check (stop if raised) Laboratory ranges vary; heavy exercise or alcohol in the prior 24–48 hours can raise values
TSH 0.4–4.0 mIU/L (standard reference range) Safety check (rat thyroid-suppression signal) Same range used as trial eligibility (NCT04715126); morning draw preferred
HbA1c No established target; track change from own baseline Expected to change (diabetes only); safety check with diabetes drugs No fasting needed; reflects about 3 months
LVEF 50–70% (standard reference range) Expected to change (cardiac patients) LVEF: left ventricular ejection fraction; measured by echocardiogram only when clinically indicated
INR (warfarin users) No established target for arjuna use; compare with own stable INR Safety check (bleeding risk) INR: international normalized ratio; check within 1–2 weeks of starting

Qualitative markers:

  • Angina frequency and use of rescue nitroglycerin
  • Exercise tolerance and perceived exertion during usual workouts
  • Day-to-day fatigue and energy
  • Dizziness on standing (possible excess blood-pressure lowering)
  • Stomach discomfort, constipation or headache
  • Unusual bruising or bleeding

Emerging Research

  • No active registered trials: A ClinicalTrials.gov search in October 2026 found no recruiting or active arjuna trials; two completed Oxyjun trials, NCT05621395 (74 adults, exercise capacity, 2023) and NCT06496880 (64 adults with metabolic risk, LVEF, 2025), have no posted or published results.
  • Oxyjun aerobic fitness trial: NCT03854786 tested 400 mg/day on VO2 max in overweight adults; terminated in 2020 because of COVID-19 after enrolling 11 participants, with no results posted.
  • Oxyjun cardiovascular trial: NCT04715126 (81 enrolled, primary endpoint LVEF) completed in 2021; its results were published (Srivastava et al., 2022) and are reported under Benefits.
  • Herbal versus drug therapy in metabolic syndrome: NCT06515652, a 200-participant multicentre trial comparing five herbs including arjuna 2 g/day with rosuvastatin, telmisartan and sitagliptin/metformin; completion date August 2024 has passed, status unknown, no results posted.
  • Heart failure trials: The 2026 meta-analyses (Kumar et al., 2026; Tang et al., 2026) rest on small trials; a large standardized-extract trial could confirm or overturn the null 12-week result (Maulik et al., 2016).
  • Hard cardiovascular outcomes: Detecting fewer heart attacks or deaths would need roughly 14,000 patients (Kaur et al., 2014); no such trial exists, so effects on events remain unknown in both directions.
  • Human interaction studies: Microsome CYP inhibition (Varghese et al., 2015) awaits human pharmacokinetic testing; a positive result would strengthen interaction warnings for statins, beta-blockers and warfarin, a null result would weaken them.
  • Thyroid and liver safety: Rat findings of thyroid suppression and liver stress at high doses (Parmar et al., 2006) remain untested in humans; thyroid-hormone measurement in future trials would confirm or dismiss this concern.
  • Blood-pressure replication: A recent triple-blind add-on trial reported extra blood-pressure lowering with telmisartan (Nazir et al., 2026); independent, larger replication would show whether the effect is reliable or a small-trial artefact.

Conclusion

Arjuna is the bark of an Indian tree with a long history as a traditional heart remedy, now sold as powders and extracts. The human evidence comes almost entirely from small studies, most run in India, often lasting only weeks and using products whose content was poorly defined.

Within that evidence, the clearest signal is modest: a branded extract improved a measure of the heart’s pumping strength and perceived effort in healthy adults, but those studies came from the company that sells it, and the change has not been tied to fewer heart problems. Reports of less chest pain, better heart failure symptoms, lower cholesterol, lower blood pressure and better blood sugar exist, yet each is either unrepeated by independent groups or contradicted by larger or combined studies, so all remain unsettled. The largest heart failure study, which found no benefit, had an author from an herbal-medicine maker.

Short-term side effects look minor: mild stomach discomfort and constipation are the main complaints, and liver and kidney tests stayed stable in people taking arjuna for up to several years. The open questions concern what has not been studied in people: effects on how the liver clears common heart and anti-clotting medicines, possible thyroid suppression seen in animals, and metal contamination in some traditional products.

For health-focused adults already managing heart risk with established measures, arjuna is an inexpensive, plausibly helpful but unproven add-on, and its possible effects on other medicines matter most for those taking several heart medicines.

Top - Benefits - Risks - Protocol